Jeffrey Lancet, MD, discusses the findings from a phase III trial of CPX-351 versus 7+3 in older patients with high-risk, secondary acute myeloid leukemia
CPX-351: A Potential Game-Changer for Older Patients With Newly Diagnosed Secondary AML?
Recent Articles
Is It Too Soon to Celebrate the Cancer Death Rate Decline?
Earlier this year, the American Cancer Society reported the biggest one-year decline in cancer mortality ever recorded from 2016 to 2017. While fewer deaths...
Trump Administration Fetal Tissue Restrictions Disrupt Research
A recent decision by the Trump administration to limit funding for research using fetal tissue is changing scientists’ research paths and disrupting research into...
U.S. Justice Department to Act Against Generic Drug Price Fixing
As part of a larger effort to attack competition issues in several markets, the antitrust division of the U.S. Department of Justice is planning...
FDA and NIH Fail to Enforce Clinical Trial Results Reporting Rules
A Science investigation showed that, while the U.S. government requires companies, universities, and other institutions that conduct clinical trials to record results in a...
Study Finds Higher Rates of Leukemia in 9/11 Responders and Recovery Workers
Investigators discovered an increase in the incidence of leukemia in first responders and other recovery workers who were at the World Trade Center (WTC)...
Current Issue
January 2020 Annual Meeting Edition
This issue features highlights from the 2019 ASH Annual Meeting, reflections on physician wellness, and more.
